In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis

Alfonso Iovieno, Alessandro Lambiase, Alessandra Micera, Barbara Stampachiacchiere, Roberto Sgrulleta, Stefano Bonini

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose. Matrix metalloproteinases (MMPs) have a role in the pathogenesis of rosacea-associated chronic blepharitis. Doxycycline is largely used as a treatment for recalcitrant chronic blepharitis. It has been shown in vitro that doxycycline inhibits MMPs activation. The aim of this study was to investigate in vivo the effect of doxycycline in modulating MMPs in patients with chronic idiopathic blepharitis. Methods. Eight patients (6 male, 2 female; mean age 45.7±17.5 years) were included in the study. Doxycycline (100 mg) was administered orally, twice a day, for 2 weeks and once a day for an additional 2 weeks. Clinical signs and symptoms were evaluated and scored (0-3) at baseline and after 4 weeks. Total sign (TSS) and total symptom (TSyS) scores were calculated. Tear samples and conjunctival impression cytologies were collected at baseline and after 4 weeks of treatment to evaluate MMP-9 and TIMP-1 expression and activity. Results. An improvement in TSS (4.5±1.1 vs 2.7±1.5) and TSyS (6.6±1.3 vs. 3.1±1.9) was observed after 4 weeks, with significant amelioration of hyperemia, marginal blepharitis, and superficial punctuate keratopathy. Zymography revealed a decrease of MMP-9 activity after 4 weeks. MMP-9 mRNA and protein levels did not change, while an upregulation of TIMP-1 expression was observed. Conclusions. This study suggests that 4-week treatment with doxycycline significantly improved symptoms and signs in patients with chronic blepharitis in association with a decrease in MMP-9 activity. Upregulation of TIMP-1 is proposed as a possible mechanism of MMP-9 inactivation.

Original languageEnglish
Pages (from-to)708-716
Number of pages9
JournalEuropean Journal of Ophthalmology
Volume19
Issue number5
Publication statusPublished - 2009

Fingerprint

Blepharitis
Doxycycline
Matrix Metalloproteinase 9
Metalloproteases
Tears
Tissue Inhibitor of Metalloproteinase-1
Matrix Metalloproteinases
Signs and Symptoms
Up-Regulation
Rosacea
Hyperemia
Cell Biology
Therapeutics
Messenger RNA
Proteins

Keywords

  • Chronic blepharitis
  • Doxycycline
  • Impression cytology
  • MMP-9
  • Tears
  • TIMP-1

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Iovieno, A., Lambiase, A., Micera, A., Stampachiacchiere, B., Sgrulleta, R., & Bonini, S. (2009). In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. European Journal of Ophthalmology, 19(5), 708-716.

In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. / Iovieno, Alfonso; Lambiase, Alessandro; Micera, Alessandra; Stampachiacchiere, Barbara; Sgrulleta, Roberto; Bonini, Stefano.

In: European Journal of Ophthalmology, Vol. 19, No. 5, 2009, p. 708-716.

Research output: Contribution to journalArticle

Iovieno, A, Lambiase, A, Micera, A, Stampachiacchiere, B, Sgrulleta, R & Bonini, S 2009, 'In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis', European Journal of Ophthalmology, vol. 19, no. 5, pp. 708-716.
Iovieno, Alfonso ; Lambiase, Alessandro ; Micera, Alessandra ; Stampachiacchiere, Barbara ; Sgrulleta, Roberto ; Bonini, Stefano. / In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. In: European Journal of Ophthalmology. 2009 ; Vol. 19, No. 5. pp. 708-716.
@article{f783dfe709d644b4a932e20f31183bed,
title = "In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis",
abstract = "Purpose. Matrix metalloproteinases (MMPs) have a role in the pathogenesis of rosacea-associated chronic blepharitis. Doxycycline is largely used as a treatment for recalcitrant chronic blepharitis. It has been shown in vitro that doxycycline inhibits MMPs activation. The aim of this study was to investigate in vivo the effect of doxycycline in modulating MMPs in patients with chronic idiopathic blepharitis. Methods. Eight patients (6 male, 2 female; mean age 45.7±17.5 years) were included in the study. Doxycycline (100 mg) was administered orally, twice a day, for 2 weeks and once a day for an additional 2 weeks. Clinical signs and symptoms were evaluated and scored (0-3) at baseline and after 4 weeks. Total sign (TSS) and total symptom (TSyS) scores were calculated. Tear samples and conjunctival impression cytologies were collected at baseline and after 4 weeks of treatment to evaluate MMP-9 and TIMP-1 expression and activity. Results. An improvement in TSS (4.5±1.1 vs 2.7±1.5) and TSyS (6.6±1.3 vs. 3.1±1.9) was observed after 4 weeks, with significant amelioration of hyperemia, marginal blepharitis, and superficial punctuate keratopathy. Zymography revealed a decrease of MMP-9 activity after 4 weeks. MMP-9 mRNA and protein levels did not change, while an upregulation of TIMP-1 expression was observed. Conclusions. This study suggests that 4-week treatment with doxycycline significantly improved symptoms and signs in patients with chronic blepharitis in association with a decrease in MMP-9 activity. Upregulation of TIMP-1 is proposed as a possible mechanism of MMP-9 inactivation.",
keywords = "Chronic blepharitis, Doxycycline, Impression cytology, MMP-9, Tears, TIMP-1",
author = "Alfonso Iovieno and Alessandro Lambiase and Alessandra Micera and Barbara Stampachiacchiere and Roberto Sgrulleta and Stefano Bonini",
year = "2009",
language = "English",
volume = "19",
pages = "708--716",
journal = "European Journal of Ophthalmology",
issn = "1120-6721",
publisher = "Wichtig Publishing",
number = "5",

}

TY - JOUR

T1 - In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis

AU - Iovieno, Alfonso

AU - Lambiase, Alessandro

AU - Micera, Alessandra

AU - Stampachiacchiere, Barbara

AU - Sgrulleta, Roberto

AU - Bonini, Stefano

PY - 2009

Y1 - 2009

N2 - Purpose. Matrix metalloproteinases (MMPs) have a role in the pathogenesis of rosacea-associated chronic blepharitis. Doxycycline is largely used as a treatment for recalcitrant chronic blepharitis. It has been shown in vitro that doxycycline inhibits MMPs activation. The aim of this study was to investigate in vivo the effect of doxycycline in modulating MMPs in patients with chronic idiopathic blepharitis. Methods. Eight patients (6 male, 2 female; mean age 45.7±17.5 years) were included in the study. Doxycycline (100 mg) was administered orally, twice a day, for 2 weeks and once a day for an additional 2 weeks. Clinical signs and symptoms were evaluated and scored (0-3) at baseline and after 4 weeks. Total sign (TSS) and total symptom (TSyS) scores were calculated. Tear samples and conjunctival impression cytologies were collected at baseline and after 4 weeks of treatment to evaluate MMP-9 and TIMP-1 expression and activity. Results. An improvement in TSS (4.5±1.1 vs 2.7±1.5) and TSyS (6.6±1.3 vs. 3.1±1.9) was observed after 4 weeks, with significant amelioration of hyperemia, marginal blepharitis, and superficial punctuate keratopathy. Zymography revealed a decrease of MMP-9 activity after 4 weeks. MMP-9 mRNA and protein levels did not change, while an upregulation of TIMP-1 expression was observed. Conclusions. This study suggests that 4-week treatment with doxycycline significantly improved symptoms and signs in patients with chronic blepharitis in association with a decrease in MMP-9 activity. Upregulation of TIMP-1 is proposed as a possible mechanism of MMP-9 inactivation.

AB - Purpose. Matrix metalloproteinases (MMPs) have a role in the pathogenesis of rosacea-associated chronic blepharitis. Doxycycline is largely used as a treatment for recalcitrant chronic blepharitis. It has been shown in vitro that doxycycline inhibits MMPs activation. The aim of this study was to investigate in vivo the effect of doxycycline in modulating MMPs in patients with chronic idiopathic blepharitis. Methods. Eight patients (6 male, 2 female; mean age 45.7±17.5 years) were included in the study. Doxycycline (100 mg) was administered orally, twice a day, for 2 weeks and once a day for an additional 2 weeks. Clinical signs and symptoms were evaluated and scored (0-3) at baseline and after 4 weeks. Total sign (TSS) and total symptom (TSyS) scores were calculated. Tear samples and conjunctival impression cytologies were collected at baseline and after 4 weeks of treatment to evaluate MMP-9 and TIMP-1 expression and activity. Results. An improvement in TSS (4.5±1.1 vs 2.7±1.5) and TSyS (6.6±1.3 vs. 3.1±1.9) was observed after 4 weeks, with significant amelioration of hyperemia, marginal blepharitis, and superficial punctuate keratopathy. Zymography revealed a decrease of MMP-9 activity after 4 weeks. MMP-9 mRNA and protein levels did not change, while an upregulation of TIMP-1 expression was observed. Conclusions. This study suggests that 4-week treatment with doxycycline significantly improved symptoms and signs in patients with chronic blepharitis in association with a decrease in MMP-9 activity. Upregulation of TIMP-1 is proposed as a possible mechanism of MMP-9 inactivation.

KW - Chronic blepharitis

KW - Doxycycline

KW - Impression cytology

KW - MMP-9

KW - Tears

KW - TIMP-1

UR - http://www.scopus.com/inward/record.url?scp=70549085965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70549085965&partnerID=8YFLogxK

M3 - Article

C2 - 19787586

AN - SCOPUS:70549085965

VL - 19

SP - 708

EP - 716

JO - European Journal of Ophthalmology

JF - European Journal of Ophthalmology

SN - 1120-6721

IS - 5

ER -